Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wharton's jelly-derived mesenchymal stem cells (PBKM)
- Development stage
- Unknown
- Lead developer
- Polski Bank Komórek Macierzystych
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) is an investigational cell-based therapy developed by Polski Bank Komorek Macierzystych (PBKM) for the treatment of amyotrophic lateral sclerosis (ALS). Classified as an Advanced Therapy Medicinal Product (ATMP), the therapy consists of mesenchymal stem cells isolated from the Wharton's jelly of umbilical cord tissue. These cells are administered via intrathecal injection and are thought to function by inhibiting motor neuron apoptosis, reducing the expression of inflammatory factors, and increasing the expression of neurotrophic factors, thereby providing a neuroprotective environment. The product is currently being evaluated in Phase 1/2 clinical trials to assess its safety and impact on the immune system of ALS patients.
- Other names
- Wharton's jelly-derived mesenchymal stem cellsWJ-MSCsWJMSCsMesenchymal stem cells isolated from Wharton's jelly
Beyond the preview
Go deeper on Wharton's jelly-derived mesenchymal stem cells (PBKM).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wharton's jelly-derived mesenchymal stem cells (PBKM).